Qicong Hu is a core member of Boston Consulting Group’s Health Care practice in Greater China, as well as a member of the Corporate Finance & Strategy practice. He has supported the strategy, operations, and organization transformation of leading pharmaceutical, medtech, and life sciences companies, and large health care providers, providing guidance on topics including group and business unit strategies, corporate development, inbound and outbound M&A, new product launch, market access, due diligence, operations, organization restructuring, R&D strategy, portfolio planning, and medical strategy.

Since joining BCG in 2012, Qicong has worked with local Chinese biotech companies as they grow and go abroad. He led the transformation of a generics pharma client into an innovative player, and helped a multinational company better localize and adapt to the Chinese market.

Before joining the firm, Qicong was a researcher at Stanford University.

AREAS OF EXPERTISE

  • R&D/portfolio strategy
  • AI drug discovery
  • M&A/licensing
  • New product launch and go-to-market
  • Innovation transformation
  • Emerging biotech (such as cell and gene therapy, RNAi, mRNA)
  • Digital marketing
  • In-vitro diagnosis/next generation sequencing
  • Life science tools/bioprocess
  • Health tech/digital health
  • Market access/pricing/innovative payment

EDUCATION

  • PhD, biomedical sciences, Stanford University